Lv1
38 积分 2026-02-16 加入
Exploring the next generation of antibody–drug conjugates
6小时前
待确认
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
10小时前
已完结
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
1个月前
已关闭
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
1个月前
已关闭
New payloads drive next-gen antibody–drug conjugates
1个月前
已完结
Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes
2个月前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
3个月前
已完结
Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer
3个月前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
3个月前
已完结
Macrophages: Targets for next-generation cancer immunotherapy
3个月前
已完结
皖公网安备34019202002308
